Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (vol 37, pg 2097, 2018)

著录项

• 来源
  《European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology》 |2019年第1期|共1页
• 作者

  Vehreschild Maria J. G. T.; Taori Surabhi; Goldenberg Simon D.; Thalhammer Florian; Bouza Emilio; van Oene Joop; Wetherill Graham; Georgopali Areti;

  展开▼
• 作者单位

  Univ Hosp Cologne Dept Internal Med 1 Cologne Germany;

  Kings Coll Hosp NHS Fdn Trust London England;

  Kings Coll London London England;

  Med Univ Vienna Div Internal Med 1 Dept Infect Dis &

  Trop Med Vienna Austria;

  Hosp Gregorio Maranon Clin Microbiol &

  Infect Dis Madrid Spain;

  Astellas Pharma Europe BV Leiden Netherlands;

  Astellas Pharma Europe BV Leiden Netherlands;

  Astellas Pharma Inc Chertsey England;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 医学微生物学（病原细菌学、病原微生物学）;
• 关键词